Références Chapitre 10


  1. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. 2011 Update. Geneva, Switzerland 2011.
    http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf

  2. Dooley KE, Mitnick CD, DeGroote MA, et al. and on behalf of the Efficacy Subgroup, RESIST-TB. Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis. Clinical Infectious Diseases 2012;55(4):572–81.

  3. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46(4): 1022-5.

  4. Baohong JI, Nacer L, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset JH. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:2006-2069.

  5. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99.

  6. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003 Oct;124(4):1476-81.

  7. US FDA. Highlights of prescribing information.
    http://www.who.int/tb/challenges/mdr/Package_insert_bedaquiline.pdf

  8. World Health Organization. Interim guidance on the use of bedaquiline to treat MDR-TB. Geneva, 2013.
    http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html

  9. Sundari Mase, Terence Chorba, Philip Lobue, Kenneth Castro. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR Recommendations and Reports, October 25, 2013 / 62(rr09);1-12.
    http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm

  10. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134:187-92.

  11. Fortún J, Martín-Dávila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-5.

  12. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4.

  13. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50:49-55.

  14. G Sotgiu, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. ERJ April 10, 2012.

  15. H. Cox, N. Ford: Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.

  16. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.

  17. Chang KC, Leung CC, Daley CL. Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 502-503.

  18. Lee M, Lee J, Carroll MW, et al. Linezolid for Treatment of Chronic Extensively Drug- Resistant Tuberculosis. N Engl J Med 2012;367:1508-18.

  19. Katiyar SK, Bihari S, Prakash S, et al. A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-reisistant tuberculosis. Int J Tuberc Lung Dis 12(2): 139-145.

  20. Rom WN, Garay S, Eds. Tuberculosis. Philadelphia, Lippincott Williams & Wilkins; 2004. p 751.

  21. Organisation mondiale de la Santé. Principes directeurs à l'intention des programmes antituberculeux pour la prise en charge des tuberculoses pharmacorésistantes. Mise à jour 2008. (WHO/HTM/TB/2008.402).
    http://whqlibdoc.who.int/publications/2009/9789242547580_fre.pdf

  22. Nunn PP, Kibuga D, Gathua S, et al. Thiacetazone commonly causes cutaneous hypersensitivity reactions in HIV positive patients treated for tuberculosis. Lancet 1991; 337: 627-630.

  23. A Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim, Pankaj Kumar Das, Mihir Ranjan Sarker, P Daru, and HL Rieder: Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis Am J Respir Crit Care Med Vol 182. pp 684–692, 2010.
    http://ajrccm.atsjournals.org/content/182/5/684.full.pdf

  24. F Kassa, D Affolabi, G Ade, S Anagonou, M Gninafon, A Trebucq. Successful 12-month treatment for multidrug-resistant tuberculosis patients in Benin National TB Programme, Ministry of Health, Cotonou, Benin. Abstract PC-728-16 International U presented at the International Union Against Tuberculosis and Lung Disease Conference, Kuala Lumpur, Malaysia. November 2012.

  25. World Health Organization. The use of short regimens for treatment of multidrug-resistant tuberculosis.
    http://www.who.int/tb/challenges/mdr/short_regimen_use/en/

  26. Francis RS, Curwen MP. Major surgery for pulmonary tuberculosis: final report. A national survey of 8232 patients operated on from April 1953 to March 1954 and followed up for five years. Tubercle 1964; supplement 45: 5-79.

  27. ED Chan, V Laurel, MJ Strand, JF Chan,Mai-Lan N. Huynh, M Goble, and MD Iseman: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103–1109.
    http://ajrccm.atsjournals.org/content/169/10/1103.long

  28. Pomerantz, B., Cleveland, J., Olson, H., Pomernatz, M. Pulmonary resection for multidrugresistant tuberculosis. Journal of Thoracic and Cardiovascular Surgery 2001; 121(3): 448-53.

  29. Somocurcio J, Sotomayor A, Shin S et al. Surgical Therapy for Patients with Drug-Resistant Tuberculosis: Report of 121 Cases Receiving Community- Based Treatment in Lima, Peru. Thorax published online 23 Aug 2006.

  30. Kim H, Kang C, Kim Y et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006; 28: 576–580.

  31. Holdiness MR. Cerebrospinal fluid pharmokinetics of antituberculoisis drugs. Clin Pharmacokinet 1985;10:532-534.

  32. Daley CL. Mycobacterium tuberculosis Complex. In: Antimicrobial Therapy and Vaccines. Yu VL, Merigan Jr, TC, Barriere, SL, editors., Philadelphia: Williams & Wilkins, 1999; pp. 531-536.

  33. Migliori GB et al. Extensively drug-resistant tuberculosis, Italy and Germany [letter]. In: Emerging Infectious Diseases [serial on the Internet], May 2007.

  34. Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008 Jan 1;46(1):42-9.

  35. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. Morbidity and Mortality Weekly Report, 2006, 55(11):301–305.